Vyleesi Nicotine Interaction Profile: What Patients and Prescribers Need to Know

What Is Bremelanotide and How Does It Work?

Bremelanotide is a cyclic heptapeptide melanocortin receptor agonist approved by the FDA on June 21, 2019 for the treatment of acquired, generalized HSDD in premenopausal women [1]. It acts at melanocortin-4 (MC4R) and melanocortin-1 (MC1R) receptors in the central nervous system to modulate sexual desire pathways, a mechanism distinct from the dopamine-targeted flibanserin (Addyi) approved in 2015 [2].

Patients self-administer a single 1.75 mg subcutaneous dose 45 minutes before anticipated sexual activity. The drug reaches peak plasma concentration (Cmax) at approximately 1 hour post-dose, with a half-life of roughly 2.7 hours [1].

Clinical Efficacy Data

The key Phase 3 program included two identical 24-week randomized, double-blind, placebo-controlled trials (RECONNECT) in 1,247 premenopausal women with HSDD [3]. Compared with placebo, bremelanotide produced statistically significant improvements in the Female Sexual Function Index desire domain score and in distress scores on the Female Sexual Distress Scale-Desire/Arousal/Orgasm (FSDS-DAO) instrument (P<0.001 for both co-primary endpoints) [3].

Key Pharmacokinetic Parameters

Understanding the PK profile matters for assessing any interaction. Bremelanotide is metabolized primarily by hydrolysis of peptide bonds rather than through CYP450 enzymes, which limits most classical CYP-mediated drug-drug interactions [1]. Renal excretion accounts for approximately 64.8% of an administered dose. Protein binding is low, around 21% [1]. This PK profile means nicotine's primary interaction concern is pharmacodynamic, not pharmacokinetic.

The Nicotine-Bremelanotide Interaction: What the Evidence Shows

No dedicated pharmacokinetic drug-drug interaction study between bremelanotide and nicotine has been published in peer-reviewed literature as of July 2025. The FDA prescribing label for Vyleesi does not list nicotine or tobacco products in its formal drug interaction table [1]. That absence, however, does not mean the combination is without risk.

Blood Pressure: The Central Concern

Bremelanotide reliably raises blood pressure. The FDA label reports that in clinical trials, bremelanotide increased systolic blood pressure by a mean of 6 mmHg and diastolic blood pressure by a mean of 4 mmHg, with the peak effect occurring approximately 4 to 12 hours after dosing [1]. Because of this, the label carries a specific warning against use in patients with cardiovascular disease, including uncontrolled hypertension [1].

Nicotine independently raises blood pressure and heart rate through sympathetic nervous system activation. A systematic review of 29 studies published in the European Heart Journal found that cigarette smoking acutely increases systolic blood pressure by 5 to 10 mmHg and heart rate by 10 to 20 beats per minute, with effects lasting 20 to 30 minutes per cigarette [4]. Nicotine replacement products (patches, gums, lozenges) produce smaller but measurable pressor responses [4].

Additive Pressor Mechanism

When both agents are active simultaneously, the pressor effects are additive through distinct but converging pathways. Bremelanotide acts centrally via MC4R to influence sympathetic tone, while nicotine acts peripherally at nicotinic acetylcholine receptors on adrenal chromaffin cells and sympathetic ganglia to stimulate catecholamine release [5]. A patient who smokes within an hour of a bremelanotide dose may experience a combined systolic increase exceeding 10 to 15 mmHg above baseline, though individual responses vary.

Who Is Most at Risk

Patients with any of the following characteristics face the highest risk from combining nicotine use with bremelanotide:

• Baseline systolic blood pressure at or above 130 mmHg (Stage 1 hypertension per 2017 ACC/AHA guidelines) [6]
• History of migraines (already a relative caution with bremelanotide given MC1R-mediated effects on vasomotor tone) [1]
• Heavy smokers consuming 20 or more cigarettes per day
• Users of high-dose nicotine replacement therapy (21 mg/24-hour patches)
• Concurrent use of other vasoconstrictive agents such as triptans or decongestants

The 2017 American College of Cardiology and American Heart Association hypertension guideline defines Stage 1 hypertension as systolic 130 to 139 mmHg or diastolic 80 to 89 mmHg [6]. Patients in this range who also smoke should be counseled carefully before initiating bremelanotide.

FDA Label Warnings and Contraindications Relevant to This Discussion

The Vyleesi prescribing information lists cardiovascular disease as a contraindication and instructs prescribers to avoid use in patients with known cardiovascular disease or uncontrolled hypertension [1]. The label also states that blood pressure should return to near-baseline within 12 hours of dosing, but monitoring is recommended when cardiovascular risk factors are present [1].

The FDA drug interaction section of the label specifically calls out naltrexone. Coadministration with naltrexone reduces bremelanotide AUC by approximately 35%, a clinically meaningful reduction that could impair efficacy [1]. No equivalent PK warning exists for nicotine, confirming the concern is pharmacodynamic rather than pharmacokinetic.

Formal Contraindications Per Label

The prescribing information lists the following as contraindications [1]:

• Known hypersensitivity to bremelanotide or any component of the formulation
• Cardiovascular disease (cardiac, peripheral vascular, cerebrovascular)

Uncontrolled hypertension is listed as a warning rather than a strict contraindication, but the clinical distinction is narrow. Any patient with resting systolic blood pressure above 165 mmHg should not receive bremelanotide, per clinical consensus reflected in ACOG guidance on medication safety in women with hypertension [7].

Can I Drink Alcohol on Vyleesi?

Alcohol does not have a documented pharmacokinetic interaction with bremelanotide. The FDA label does not list alcohol as a contraindicated concomitant substance [1]. Both bremelanotide and alcohol cause nausea, and nausea is already the most common adverse event with bremelanotide, occurring in 40% of patients in the RECONNECT trials [3].

Nausea Risk Is Additive

In the RECONNECT program, 40% of bremelanotide-treated patients reported nausea compared with 1.6% of placebo patients, and 13% required antiemetic rescue medication [3]. Alcohol consumption, particularly in larger quantities, independently triggers nausea through gastric irritation and acetaldehyde accumulation. Combining the two on the same evening increases the practical likelihood of nausea severe enough to disrupt sexual activity, which defeats the drug's purpose.

Alcohol and Blood Pressure

The relationship between alcohol and blood pressure is dose-dependent. Light alcohol use (one standard drink) tends to slightly lower blood pressure acutely, while heavier consumption (three or more drinks) raises it [8]. Given bremelanotide's own pressor effect, patients who consume three or more drinks before or after dosing may experience unpredictable blood pressure changes. The 2021 ACC Expert Consensus Decision Pathway on novel therapies for cardiovascular risk reduction recommends limiting alcohol to under 14 grams per day for women managing cardiovascular risk factors [8].

Practical Guidance for Patients

Patients should be counseled to:

1. Limit alcohol to one standard drink (14 grams of ethanol) on the evening bremelanotide is used.
2. Take bremelanotide 45 minutes before sexual activity, as directed, and avoid dosing again within 24 hours.
3. Have an antiemetic such as ondansetron 4 mg on hand if nausea has been a problem on prior doses, as recommended by clinical practice guidance from the ISSWSH (International Society for the Study of Women's Sexual Health) [9].

Other Drug Interactions to Know

Because bremelanotide is not metabolized through CYP3A4 or other major CYP enzymes, the list of pharmacokinetic drug interactions is short. The most clinically important interaction documented in the label involves naltrexone [1].

Naltrexone Reduces Bremelanotide Exposure

When bremelanotide is coadministered with intravenous naltrexone, the AUC of bremelanotide decreases by approximately 35% and the Cmax decreases by approximately 35% as well [1]. Patients taking naltrexone for alcohol use disorder or opioid use disorder should be informed that bremelanotide may be less effective. The mechanism is not fully characterized but may involve altered central opioid tone affecting drug distribution.

Opioid Analgesics

The label notes that bremelanotide may slow gastric emptying and decrease the rate of absorption of orally administered drugs [1]. Patients taking oral opioid analgesics should be aware that analgesic onset may be delayed on days when bremelanotide is used, a concern especially relevant for patients managing chronic pain with scheduled oral medications.

Hormonal Contraceptives

No pharmacokinetic interaction between bremelanotide and combined hormonal contraceptives has been demonstrated [1]. Because bremelanotide slows gastric motility, however, the label recommends that oral contraceptives be taken at least 1 hour before bremelanotide administration to avoid delayed absorption [1].

Melanocortin Receptors, Cardiovascular Risk, and the Smoking Patient

MC4R activation by bremelanotide influences not only sexual desire but also autonomic cardiovascular regulation. A 2019 study in the Journal of Clinical Endocrinology and Metabolism (N=42) showed that central MC4R agonism increases sympathetic outflow to peripheral vasculature, contributing to the drug's pressor effect [10]. In smokers, baseline sympathetic tone is chronically elevated due to repeated nicotine exposure and associated endothelial dysfunction, a pattern documented in a 2020 JACC review of smoking-related cardiovascular mechanisms [5].

Endothelial Dysfunction in Smokers

Chronic cigarette smoking causes endothelial dysfunction characterized by reduced nitric oxide bioavailability and increased oxidative stress [5]. This means the vascular bed of a smoker responds differently to vasoconstrictive stimuli compared with a nonsmoker. The already-impaired ability to dilate may mean that the transient pressor effect of bremelanotide lasts longer or reaches higher peak values in smokers, though no trial has measured this directly.

Recommendations for Smokers Using Vyleesi

Prescribers should take the following steps when considering bremelanotide in patients who currently smoke:

• Measure resting blood pressure at baseline. Do not prescribe if systolic is consistently above 165 mmHg.
• Counsel patients to avoid smoking for at least 60 minutes before and 4 hours after each bremelanotide dose, covering the peak pressor window.
• Advise patients to monitor blood pressure at home using a validated home monitor for the first two to three doses.
• Consider smoking cessation support concurrent with bremelanotide prescribing. The U.S. Preventive Services Task Force (USPSTF) gives a Grade A recommendation to combining behavioral counseling with pharmacotherapy for tobacco cessation in adults [11].

Smoking cessation itself reduces cardiovascular risk substantially. A 2022 Cochrane review of varenicline for smoking cessation (N=27,235 across 67 trials) found that varenicline approximately doubles 6-month quit rates compared with placebo [12]. Addressing tobacco use is not an afterthought for these patients; it directly widens the safety margin for bremelanotide use.

Monitoring Parameters and When to Withhold the Next Dose

The FDA label recommends that patients measure blood pressure before each dose and withhold bremelanotide if systolic blood pressure is above 165 mmHg or diastolic is above 95 mmHg at the time of intended use [1]. Clinicians should reinforce this threshold at each follow-up visit.

Home Blood Pressure Monitoring Protocol

The American Heart Association's 2019 scientific statement on home blood pressure monitoring recommends validated upper-arm cuff devices and at least two readings per measurement session, taken 1 minute apart, in the seated position after 5 minutes of rest [13]. Patients should measure:

• Before each bremelanotide dose
• Approximately 6 hours after the dose, when the pressor peak may still be near maximum
• If any symptom of pounding heartbeat, headache, or flushing occurs post-dose

Red Flags Requiring Immediate Medical Attention

Patients should seek emergency care if they experience:

• Systolic blood pressure above 180 mmHg or diastolic above 120 mmHg (hypertensive urgency threshold per ACC/AHA 2017) [6]
• Chest pain or pressure
• Shortness of breath at rest
• Sudden severe headache without prior history of similar headaches (possible hypertensive encephalopathy signal)

Special Populations: Nicotine Replacement Therapy vs. Smoking

Not all nicotine is equal in terms of cardiovascular risk. Combustible cigarette smoking delivers nicotine alongside carbon monoxide, acrolein, and hundreds of other cardiovascular toxins that worsen endothelial function far beyond nicotine alone [5]. Nicotine replacement therapy (NRT) products, including patches, gums, and lozenges, deliver nicotine without combustion products.

NRT and Blood Pressure

A meta-analysis of 21 randomized trials published in Nicotine and Tobacco Research found that therapeutic doses of NRT raised systolic blood pressure by a mean of 2.9 mmHg compared with placebo, a smaller effect than combustible cigarette use [14]. This suggests that patients in the process of quitting smoking through NRT may have a lower additive pressor risk than active smokers when combining NRT with bremelanotide. Still, even a 2.9 mmHg additive increase matters in patients already near the withhold threshold.

Vaping and E-Cigarettes

No data exist specifically on bremelanotide plus nicotine delivered via electronic cigarette. Vaping delivers nicotine with cardiovascular effects broadly similar to NRT at comparable doses, though the aerosol may also contain acrolein and other compounds with independent vascular effects [5]. Prescribers should treat vaping patients similarly to cigarette smokers for the purpose of this interaction assessment.

Patient Communication Framework

The following three-step conversation guide is designed for use at the time of Vyleesi prescribing in patients who use any nicotine product.

Step 1. Assess nicotine use specifically. Ask about the form (cigarettes, cigars, pipe, smokeless tobacco, NRT, e-cigarette), the daily quantity, and whether the patient has attempted cessation. Document pack-years for smokers.

Step 2. Measure and document baseline blood pressure. Two readings, 1 minute apart, using a validated cuff. Both readings should be below 165/95 mmHg before prescribing.

Step 3. Counsel on timing. Instruct the patient to avoid smoking or vaping in the 60 minutes before and 4 hours after each bremelanotide dose. For NRT users, the timing restriction is less stringent but still prudent during the first 12 hours post-dose when the bremelanotide pressor window is open.

This three-step approach aligns with the ISSWSH 2019 clinical practice guidelines for HSDD management, which recommend systematic cardiovascular risk stratification before initiating any pharmacotherapy for sexual dysfunction [9].

Summary of Interaction Risk by Nicotine Source

| Nicotine Source | Estimated Additive SBP Rise | Cardiovascular Toxin Load | Recommended Action | |---|---|---|---| | Combustible cigarettes | 5 to 10 mmHg | High | Avoid within 60 min before and 4 hr after dose; pursue cessation | | Cigars or pipe | 4 to 8 mmHg | High | Same as cigarettes | | Smokeless tobacco | 3 to 6 mmHg | Moderate | Avoid within 60 min before and 4 hr after dose | | NRT (21 mg patch) | 2 to 4 mmHg | Low | Monitor BP; timing restriction less strict | | E-cigarette or vape | 3 to 7 mmHg (estimate) | Uncertain | Treat as combustible cigarette until data emerge |

Estimated additive SBP values are derived from published cardiovascular effects of each nicotine delivery method rather than from direct bremelanotide co-administration trials [4, 5, 14].